the antigen company

REPLACE CHEMOTHERAPY AND RADIATION THERAPY WITH PRE-CLINICALLY TESTED ANTIGEN CANCER THERAPY THAT HAS MARKEDLY FEWER SIDE EFFECTS

Axenoll owns the patent for the use “Lx TB PstS1 (Lx-Bladder) Antigen“ in cancer therapy. Due to convincing pre-clinical results, this antigen currently undergoes clinical testing for treating bladder cancer. The pre-clinical trials conducted by Lionex Diagnostics & Therapeutics suggest that cancer therapy with selected antigens has very small or no side effects. An antigen cancer treatment offers similar prospects of success and, thus, an alternative to the standard chemo and radiation treatment. In the future, the clinical use should be extended to prostate, lung and breast cancer.

Axenoll owns and buys patents and exclusive rights for cancer treatment approaches that have a high likelihood of success. After the successful completion of clinical trials (phases I and II), the results are commercialized by granting licenses to pharmaceutical companies. In this way, Axenoll aims for sustainable growth and a top position in the area of antigen cancer therapy.

Antigens and their function
Antigens (Antibody generating) are natural or artificially produced substances that the organism recognizes as alien and that trigger an immune reaction by generating antibodies. During the development of the tuberculosis vaccination cell culture BCG and research on the tuberculosis agent “Mycobacterium tuberculosis“, antigens were found that trigger an intense reaction of the immune system. Beyond tuberculosis, this means that treatment approaches for illnesses such as AIDS, arteriosclerosis, asthma or, now, cancer can be developed. The human immune system recognizes the patented molecules of the tuberculosis agent “Mycobacterium tuberculosis“ extremely quickly. They are “immunodominant“. These molecular regions can be used to alarm the immune system to previously unrecognized dangers, such as cancer cells. The organisms own “killer cells” can then eliminate the mutated cancer cells. The great advantage of the treatment approach: The pre-clinical trials conducted by Lionex support the conclusion that there are no heavy side effects in contrast to the standard chemotherapy and radiation therapy.